Olivia Keiser

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi request reprint All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population
    Olivia Keiser
    Data Centre of the Swiss HIV Cohort Study, Lausanne, Switzerland
    AIDS 18:1835-43. 2004
  2. ncbi request reprint Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study
    Olivia Keiser
    Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland
    J Acquir Immune Defic Syndr 43:550-5. 2006
  3. ncbi request reprint Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
    Margalida Rotger
    Institute of Microbiology and Section of Infectious Diseases, University Hospital, Lausanne, Switzerland
    Pharmacogenet Genomics 15:1-5. 2005
  4. pmc Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    PLoS Med 5:e148. 2008
  5. doi request reprint Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study
    Thi Tuyet Nhung Vo
    VCHAP Project, Tropical Disease Hospital, Ho Chi Minh City, Vietnam
    J Infect Dis 197:1685-94. 2008
  6. ncbi request reprint Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Switzerland
    Antivir Ther 12:1157-64. 2007
  7. ncbi request reprint Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
    Gary M Clifford
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Natl Cancer Inst 97:425-32. 2005
  8. pmc Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine ISPM, University of Berne, Finkenhubelweg 11, CH 3012 Bern, Switzerland
    Clin Infect Dis 45:1518-21. 2007
  9. doi request reprint Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration
    Paula Braitstein
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    J Womens Health (Larchmt) 17:47-55. 2008
  10. pmc Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland
    Trop Med Int Health 13:870-9. 2008

Collaborators

Detail Information

Publications13

  1. ncbi request reprint All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population
    Olivia Keiser
    Data Centre of the Swiss HIV Cohort Study, Lausanne, Switzerland
    AIDS 18:1835-43. 2004
    ..Mortality within the Swiss HIV Cohort Study for the years 1990-2001 was compared with the mortality of the general Swiss population...
  2. ncbi request reprint Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study
    Olivia Keiser
    Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland
    J Acquir Immune Defic Syndr 43:550-5. 2006
    ..According to current recommendations, HIV-infected women should have at least 1 gynecologic examination per year...
  3. ncbi request reprint Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
    Margalida Rotger
    Institute of Microbiology and Section of Infectious Diseases, University Hospital, Lausanne, Switzerland
    Pharmacogenet Genomics 15:1-5. 2005
    ..Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Allele 516 G>T (Gln172His) is associated with diminished activity of this isoenzyme, and may lead to differences in drug exposure...
  4. pmc Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    PLoS Med 5:e148. 2008
    ..We compared virologic response, changes to first-line regimens, and mortality in HIV-infected patients starting HAART in South Africa and Switzerland...
  5. doi request reprint Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study
    Thi Tuyet Nhung Vo
    VCHAP Project, Tropical Disease Hospital, Ho Chi Minh City, Vietnam
    J Infect Dis 197:1685-94. 2008
    ..Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment...
  6. ncbi request reprint Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Switzerland
    Antivir Ther 12:1157-64. 2007
    ..Antiretroviral therapy (ART) decreases morbidity and mortality in HIV-infected patients but is associated with considerable adverse events (AEs)...
  7. ncbi request reprint Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
    Gary M Clifford
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Natl Cancer Inst 97:425-32. 2005
    ....
  8. pmc Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine ISPM, University of Berne, Finkenhubelweg 11, CH 3012 Bern, Switzerland
    Clin Infect Dis 45:1518-21. 2007
    ..48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings...
  9. doi request reprint Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration
    Paula Braitstein
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    J Womens Health (Larchmt) 17:47-55. 2008
    ....
  10. pmc Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland
    Trop Med Int Health 13:870-9. 2008
    ..To describe temporal trends in baseline clinical characteristics, initial treatment regimens and monitoring of patients starting antiretroviral therapy (ART) in resource-limited settings...
  11. ncbi request reprint Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome
    Manuela Buehlmann
    Klinik und Poliklinik für Infektiologie, University Hospital of Berne, Switzerland
    HIV Clin Trials 7:48-54. 2006
    ....
  12. pmc Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  13. ncbi request reprint Reporting of observational studies in Antiviral Therapy: a case for STROBE?
    Olivia Keiser
    Antivir Ther 13:743-5. 2008